FogPharma Stock

fogpharma.comHealthcareFounded: 2016Funding to Date: $361.63MM

FogPharma is a biotechnology company developing cell-penetrating miniproteins (CPMPs) that combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules.

Register for Details

For more details on financing and valuation for FogPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for FogPharma.

Register Today


Management Team

Weiqing Zhou
Co-Founder & Chief Operating Officer
David Lane Ph.D
Milenko Cicmil Ph.D
Vice President, Translational Biology
Howard Stern
Chief Scientific Officer
Michael Hale Ph.D
Vice President, Chemistry
John McGee Ph.D
Gerard Hilinski Ph.D
Co-Founder & Senior Scientist
Gregory Verdine Ph.D
Co-Founder, President, Chief Scientific Officer, Chief Executive Officer & Chairman

Board Members

Gregory Verdine Ph.D
Krishna Yeshwant MD
Barbara Weber MD
Jeffrey Leerink
SVB Leerink
Richard Klausner MD
Edward Fitzgerald
Lianyong Chen Ph.D
6 Dimensions Capital

Other companies like FogPharma in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.
/PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice President...